NASDAQ:ALKS - Alkermes Stock Price, Forecast & News

Alkermes trades on the NASDAQ under the ticker symbol "ALKS."

Alkermes Plc (NASDAQ:ALKS) issued its earnings results on Thursday, February, 13th. The company reported $0.83 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.65 by $0.18. The company earned $412.70 million during the quarter, compared to the consensus estimate of $404.45 million. Alkermes had a positive return on equity of 1.58% and a negative net margin of 16.79%. The firm's revenue for the quarter was up 30.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 EPS. View Alkermes' Earnings History.

Alkermes is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Alkermes.

Alkermes updated its FY20 earnings guidance on Thursday, February, 13th. The company provided EPS guidance of $0.25 to $0.43 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.52. The company issued revenue guidance of $1.03 billion to $1.08 billion, compared to the consensus revenue estimate of $1.06 billion.

11 equities research analysts have issued 1-year target prices for Alkermes' stock. Their forecasts range from $19.00 to $28.00. On average, they expect Alkermes' share price to reach $23.00 in the next year. This suggests a possible upside of 13.6% from the stock's current price. View Analyst Price Targets for Alkermes.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last year. There are currently 1 sell rating, 9 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Alkermes.

News coverage about ALKS stock has trended very negative on Monday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Alkermes earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Alkermes.

Alkermes saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 5,250,000 shares, an increase of 10.5% from the December 31st total of 4,750,000 shares. Based on an average daily trading volume, of 1,570,000 shares, the short-interest ratio is presently 3.3 days. Approximately 3.4% of the shares of the company are sold short. View Alkermes' Current Options Chain.

Some companies that are related to Alkermes include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include AbbVie (ABBV), Netflix (NFLX), Celgene (CELG), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Intel (INTC), Starbucks (SBUX), Pfizer (PFE) and Advanced Micro Devices (AMD).

Alkermes' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.21%), State Street Corp (2.95%), FMR LLC (1.78%), First Trust Advisors LP (1.78%), AQR Capital Management LLC (1.22%) and Geode Capital Management LLC (1.14%). Company insiders that own Alkermes stock include David Joseph Gaffin, David W Anstice, Floyd E Bloom, James M Frates, Michael J Landine, Nancy Wysenski, Paul J Mitchell and Richard F Pops. View Institutional Ownership Trends for Alkermes.

ALKS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, UBS Asset Management Americas Inc., State Street Corp, Korea Investment CORP, UBS Group AG, Swiss National Bank, AQR Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have sold Alkermes company stock in the last year include David Joseph Gaffin, Michael J Landine, Paul J Mitchell and Richard F Pops. View Insider Buying and Selling for Alkermes.

ALKS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Krensavage Asset Management LLC, Goldman Sachs Group Inc., Russell Investments Group Ltd., Jacobs Levy Equity Management Inc., Connor Clark & Lunn Investment Management Ltd., Bank of Montreal Can and First Trust Advisors LP. View Insider Buying and Selling for Alkermes.

Shares of ALKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALKS stock can currently be purchased for approximately $20.24.

Alkermes has a market capitalization of $3.19 billion and generates $1.17 billion in revenue each year. The company earns $-196,620,000.00 in net income (profit) each year or $0.07 on an earnings per share basis. Alkermes employs 2,235 workers across the globe.View Additional Information About Alkermes.

The official website for Alkermes is http://www.alkermes.com/.

Alkermes' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. The company can be reached via phone at 353-1772-8000 or via email at [email protected]